Figure 3From: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosusMean time to improvement of each BILAG body stystem. Mean time to improvement (in days) of each BILAG body system during the follow-up of the study (N denotes the number of patients available for analysis for each body system). Since the first evaluation was scheduled for 6 weeks, the earliest time to improvement is at least 42 days.Back to article page